Pancreaticobiliary diseases
Conditions
Interventions
None listed
Sponsors
Hokkaido University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Individuals with elevated serum liver and biliary enzymes, elevated serum tumor markers (CA19-9, CEA, DUPAN-2, Span-1), and abnormalities in the pancreas or biliary tract as revealed by imaging tests (abdominal ultrasound, CT, MRI, PET-CT, EUS) 2) Individuals aged 18 years or older 3) Individuals who have received adequate explanation regarding participation in the study, have fully understood the details, and have provided written informed consent based on their own free will or that of their legal representative or proxy.
Exclusion criteria
Exclusion criteria: 1) Individuals who cannot undergo oral or nasal endoscopy. 2) Individuals who are deemed unsuitable as research subjects by the attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences of acetone, acetoacetic acid, and 3-hydroxybutyric acid concentrations in duodenal fluid among malignant and benign pancreaticobiliary diseases | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Differences of acetone, acetoacetic acid, and 3-hydroxybutyric acid concentrations in duodenal fluid among precancerous lesion and cancers at various stages 2) Differences of acetone, acetoacetic acid, and 3-hydroxybutyric acid concentrations in duodenal fluid among various pancreaticobiliary diseases 3) Differences of acetone, acetoacetic acid, and 3-hydroxybutyric acid concentrations in serum among various pancreaticobiliary diseases | — |
Countries
Japan
Contacts
Public ContactMasaki Kuwatani
Hokkaido University Hospital Department of Gastroenterology and Hepatology
Outcome results
None listed